Skip to main content
Figure 2 | BMC Endocrine Disorders

Figure 2

From: Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas

Figure 2

Phase II study of 29 patients with de novo or persistent Cushing's disease receiving pasireotide 600 μg sc bid for 15 days. Mean UFC level at baseline and study end (day 15) in each patient (n = 29) are shown. The normal range for UFC is 55-276 nmol/24 h (20-100 μg/24 h); the dashed line indicates the upper limit of the normal range. Responding patients (defined as having a UFC level within the normal range at study end) are indicated by the arrows [71]. © 2009 The Endocrine Society. Reproduced with permission.

Back to article page